Psoriasis

ROSEN, A LEADING LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX

Retrieved on: 
Sunday, March 17, 2024
Titan, Psoriasis, Class, IPO, Advertising, Court

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 16, 2024
Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points: 
  • On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
  • Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • As of the time this Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

DEADLINE ALERT for PLCE, SNOW, KIND, VTYX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Friday, March 15, 2024
Psoriasis, Law, Telephone, COVID-19, Defendant, Class, IPO, Suite, ARPU, Investment, Snowflake, Mergers and acquisitions

BENSALEM, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

DEADLINE ALERT for VTYX and IRBT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Friday, March 15, 2024
Psoriasis, Law, Amazon, Defendant, IPO, Suite, Complaint, Investment, IRobot, Security (finance)

LOS ANGELES, March 15, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, March 15, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

ROSEN, A LONGSTANDING LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX

Retrieved on: 
Friday, March 15, 2024
Titan, Psoriasis, Class, IPO, Advertising, Court

WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Ventyx class action, go to https://rosenlegal.com/submit-form/?case_id=22943 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on: 
Friday, March 15, 2024
Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

VTYX STOCKHOLDER NEWS: Contact Robbins LLP for Information Regarding the Ventyx Biosciences, Inc. Class Action

Retrieved on: 
Thursday, March 14, 2024
Psoriasis, SAN, News, LLP, IPO, Inflammation, Plaque, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points: 
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • In 2022, Ventyx initiated a Phase 2 clinical trial of VTX958 for the treatment of moderate to severe plaque psoriasis (the “Phase 2 SERENITY Trial”).
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • In addition, during the class period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline

Retrieved on: 
Wednesday, March 13, 2024
The Company, Psoriasis, Telephone, LLP, CLASS, NEXT, COST, Court, Cryptocurrency

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ventyx investors who were adversely affected by alleged securities fraud between October 21, 2021 and November 6, 2023.
  • WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Lawsuit – VTYX

Retrieved on: 
Tuesday, March 12, 2024
NEXT, Psoriasis, Fraud, Security (finance)

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ventyx Biosciences, Inc..

Key Points: 
  • NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ventyx Biosciences, Inc..
    Shareholders who purchased shares of VTYX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • DEADLINE: April 30, 2024 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is April 30, 2024.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 12, 2024
Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points: 
  • On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
  • Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • As of the time this Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.